Regulation of T cell motility in vitro and in vivo by LPA and LPA2

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Knowlden, Sara A ^a   Capece, Tara ^a   Popovic, Milan ^a   Chapman, Timothy J ^a   Rezaee, Fariba ^a   Kim, Minsoo ^a   Georas, Steve N ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOTAXIN; INTERCELLULAR ADHESION MOLECULE 1; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID 1; LYSOPHOSPHATIDIC ACID 2; LYSOPHOSPHATIDIC ACID 3; LYSOPHOSPHATIDIC ACID 4; LYSOPHOSPHATIDIC ACID 5; LYSOPHOSPHATIDIC ACID 6; LYSOPHOSPHATIDIC ACID RECEPTOR; SECONDARY LYMPHOID TISSUE CHEMOKINE; UNCLASSIFIED DRUG; LYSOPHOSPHOLIPID;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL HOMING; CELL MOTILITY; CHEMOREPULSION; CHEMOTAXIS; CONTROLLED STUDY; EMBRYO; FILTERS AND MEMBRANES; HIGH ENDOTHELIAL VENULE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE; LYMPHOCYTE MIGRATION; LYMPHOCYTE RECIRCULATION; MOUSE; MULTIPHOTON MICROSCOPY; NONHUMAN; POLARIZATION; PROTEIN DEPLETION; PROTEIN FUNCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VENULE; WILD TYPE; ANIMAL; CELL MOTION; DEFICIENCY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; NEUTROPHIL CHEMOTAXIS; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CHEMOTAXIS, LEUKOCYTE; GENE EXPRESSION; LYMPH NODES; LYSOPHOSPHOLIPIDS; MICE; MICE, KNOCKOUT; RECEPTORS, LYSOPHOSPHATIDIC ACID; T-LYMPHOCYTE SUBSETS;

EID: 84903878685     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101655     Document Type: Article

References (68)

1. Palmeri D, Zuo FR, Rosen SD, Hemmerich S (2004) Differential gene expression profile of human tonsil high endothelial cells: implications for lymphocyte trafficking. J Leukoc Biol 75: 910-927.
2. Kanda H, Newton R, Klein R, Morita Y, Gunn MD, et al. (2008) Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat Immunol 9: 415-423.
3. Nakasaki T, Tanaka T, Okudaira S, Hirosawa M, Umemoto E, et al. (2008) Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions. Am J Pathol 173: 1566-1576.
4. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, et al. (2002) Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158: 227-233.
5. Rivera-Lopez CM, Tucker AL, Lynch KR (2008) Lysophosphatidic acid (LPA) and angiogenesis. Angiogenesis 11: 301-310.
6. Ptaszynska MM, Pendrak ML, Stracke ML, Roberts DD (2010) Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration. Mol Cancer Res 8: 309-321.
7. Ren B, Hale J, Srikanthan S, Silverstein RL (2011) Lysophosphatidic acid suppresses endothelial cell CD36 expression and promotes angiogenesis via a PKD-1-dependent signaling pathway. Blood 117: 6036-6045.
8. Chen SU, Chou CH, Chao KH, Lee H, Lin CW, et al. (2008) Lysophosphatidic acid up-regulates expression of growth-regulated oncogene-alpha, interleukin-8, and monocyte chemoattractant protein-1 in human first-trimester trophoblasts: possible roles in angiogenesis and immune regulation. Endocrinology 151: 369-379.
9. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, et al. (2006) Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 281: 25822-25830.
10. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, et al. (2006) Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 26: 5015-5022.
11. Balazs L, Okolicany J, Ferrebee M, Tolley B, Tigyi G (2001) Topical application of the phospholipid growth factor lysophosphatidic acid promotes wound healing in vivo. Am J Physiol Regul Integr Comp Physiol 280: R466-472.
12. Sevastou I, Kaffe E, Mouratis MA, Aidinis V (2013) Lysoglycerophospholipids in chronic inflammatory disorders: the PLA(2)/LPC and ATX/LPA axes. Biochim Biophys Acta 1831: 42-60.
13. Zhou Z, Subramanian P, Sevilmis G, Globke B, Soehnlein O, et al. (2011) Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab 13: 592-600.
14. Cui MZ (2011) Lysophosphatidic acid effects on atherosclerosis and thrombosis. Clin Lipidol 6: 413-426.
15. Chen C, Ochoa LN, Kagan A, Chai H, Liang Z, et al. (2012) Lysophosphatidic acid causes endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Atherosclerosis 222: 74-83.
16. Mills GB, Moolenaar WH (2003) The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3: 582-591.
17. Hayashi M, Okabe K, Kato K, Okumura M, Fukui R, et al. (2012) Differential function of lysophosphatidic acid receptors in cell proliferation and migration of neuroblastoma cells. Cancer Lett.
18. Leve F, Marcondes TG, Bastos LG, Rabello SV, Tanaka MN, et al. (2011) Lysophosphatidic acid induces a migratory phenotype through a crosstalk between RhoA-Rock and Src-FAK signalling in colon cancer cells. Eur J Pharmacol 671: 7-17.
19. Goldsmith ZG, Ha JH, Jayaraman M, Dhanasekaran DN (2011) Lysophosphatidic Acid Stimulates the Proliferation of Ovarian Cancer Cells via the gep Proto-Oncogene Galpha(12). Genes Cancer 2: 563-575.
20. Oda SK, Strauch P, Fujiwara Y, Al-Shami A, Oravecz T, et al. (2013) Lysophosphatidic Acid Inhibits Cd8 T Cell Activation and Control of Tumor Progression. Cancer Immunol Res 1: 245-255.
21. Swaney JS, Chapman C, Correa LD, Stebbins KJ, Bundey RA, et al. (2010) A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br J Pharmacol 160: 1699-1713.
22. Gan L, Xue JX, Li X, Liu DS, Ge Y, et al. (2011) Blockade of lysophosphatidic acid receptors LPAR1/3 ameliorates lung fibrosis induced by irradiation. Biochem Biophys Res Commun 409: 7-13.
23. Oikonomou N, Mouratis MA, Tzouvelekis A, Kaffe E, Valavanis C, et al. (2012) Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol 47: 566-574.
24. Huang LS, Fu P, Patel P, Harijith A, Sun T, et al. (2013) Lysophosphatidic Acid Receptor 2 Deficiency Confers Protection Against Bleomycin-Induced Lung Injury and Fibrosis in Mice. Am J Respir Cell Mol Biol.
25. Tang N, Zhao Y, Feng R, Liu Y, Wang S, et al. (2014) Lysophosphatidic acid accelerates lung fibrosis by inducing differentiation of mesenchymal stem cells into myofibroblasts. J Cell Mol Med 18: 156-169.
26. Miyabe Y, Miyabe C, Iwai Y, Takayasu A, Fukuda S, et al. (2013) Necessity of lysophosphatidic Acid receptor 1 for development of arthritis. Arthritis Rheum 65: 2037-2047.
27. Nikitopoulou I, Oikonomou N, Karouzakis E, Sevastou I, Nikolaidou-Katsaridou N, et al. (2012) Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J Exp Med 209: 925-933.
28. Nikitopoulou I, Kaffe E, Sevastou I, Sirioti I, Samiotaki M, et al. (2013) A metabolically-stabilized phosphonate analog of lysophosphatidic Acid attenuates collagen-induced arthritis. PLoS One 8: e70941.
29. Orosa B, Garcia S, Martinez P, Gonzalez A, Gomez-Reino JJ, et al. (2014) Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis. Ann Rheum Dis 73: 298-305.
30. Zhao Y, Tong J, He D, Pendyala S, Evgeny B, et al. (2009) Role of lysophosphatidic acid receptor LPA2 in the development of allergic airway inflammation in a murine model of asthma. Respir Res 10: 114.
31. Emo J, Meednu N, Chapman TJ, Rezaee F, Balys M, et al. (2012) Lpa2 is a negative regulator of both dendritic cell activation and murine models of allergic lung inflammation. J Immunol 188: 3784-3790.
32. Park GY, Lee YG, Berdyshev E, Nyenhuis S, Du J, et al. (2013) Autotaxin production of lysophosphatidic acid mediates allergic asthmatic inflammation. Am J Respir Crit Care Med 188: 928-940.
33. Zhang Y, Chen YC, Krummel MF, Rosen SD (2012) Autotaxin through lysophosphatidic acid stimulates polarization, motility, and transendothelial migration of naive T cells. J Immunol 189: 3914-3924.
34. Bai Z, Cai L, Umemoto E, Takeda A, Tohya K, et al. (2013) Constitutive lymphocyte transmigration across the basal lamina of high endothelial venules is regulated by the autotaxin/lysophosphatidic acid axis. J Immunol 190: 2036-2048.
35. Knowlden S, Georas SN (2014) The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation. J Immunol 192: 851-857.
36. An S, Dickens MA, Bleu T, Hallmark OG, Goetzl EJ (1997) Molecular cloning of the human Edg2 protein and its identification as a functional cellular receptor for lysophosphatidic acid. Biochem Biophys Res Commun 231: 619-622.
37. An S, Bleu T, Hallmark OG, Goetzl EJ (1998) Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J Biol Chem 273: 7906-7910.
38. Bandoh K, Aoki J, Hosono H, Kobayashi S, Kobayashi T, et al. (1999) Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem 274: 27776-27785.
39. Noguchi K, Ishii S, Shimizu T (2003) Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 278: 25600-25606.
40. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J (2006) GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 281: 23589-23597.
41. Yanagida K, Masago K, Nakanishi H, Kihara Y, Hamano F, et al. (2009) Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J Biol Chem 284: 17731-17741.
42. Hecht JH, Weiner JA, Post SR, Chun J (1996) Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J Cell Biol 135: 1071-1083.
43. Jeong KJ, Park SY, Seo JH, Lee KB, Choi WS, et al. (2008) Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells. Exp Mol Med 40: 607-616.
44. Hope JM, Wang FQ, Whyte JS, Ariztia EV, Abdalla W, et al. (2009) LPA receptor 2 mediates LPA-induced endometrial cancer invasion. Gynecol Oncol 112: 215-223.
45. Lee SJ, Ritter SL, Zhang H, Shim H, Hall RA, et al. (2011) MAGI-3 competes with NHERF-2 to negatively regulate LPA2 receptor signaling in colon cancer cells. Gastroenterology 140: 924-934.
46. Chen RJ, Chen SU, Chou CH, Lin MC (2012) Lysophosphatidic acid receptor 2/3-mediated IL-8-dependent angiogenesis in cervical cancer cells. Int J Cancer 131: 789-802.
47. Ye X, Herr DR, Diao H, Rivera R, Chun J (2011) Unique uterine localization and regulation may differentiate LPA3 from other lysophospholipid receptors for its role in embryo implantation. Fertil Steril 95: 2107-2113, 2113 e2101-2104.
48. Guo H, Gong F, Luo KL, Lu GX (2013) Cyclic regulation of LPA3 in human endometrium. Arch Gynecol Obstet 287: 131-138.
49. Kotarsky K, Boketoft A, Bristulf J, Nilsson NE, Norberg A, et al. (2006) Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J Pharmacol Exp Ther 318: 619-628.
50. Pasternack SM, von Kugelgen I, Al Aboud K, Lee YA, Ruschendorf F, et al. (2008) G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat Genet 40: 329-334.
51. Contos JJ, Ishii I, Fukushima N, Kingsbury MA, Ye X, et al. (2002) Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2). Mol Cell Biol 22: 6921-6929.
52. Nishimasu H, Okudaira S, Hama K, Mihara E, Dohmae N, et al. (2011) Crystal structure of autotaxin and insight into GPCR activation by lipid mediators. Nat Struct Mol Biol 18: 205-212.
53. Perrakis A, Moolenaar WH (2014) Autotaxin: structure-function and signaling. J Lipid Res.
54. Mionnet C, Sanos SL, Mondor I, Jorquera A, Laugier JP, et al. (2011) High endothelial venules as traffic control points maintaining lymphocyte population homeostasis in lymph nodes. Blood 118: 6115-6122.
55. Goetzl EJ, Kong Y, Voice JK (2000) Cutting edge: differential constitutive expression of functional receptors for lysophosphatidic acid by human blood lymphocytes. J Immunol 164: 4996-4999.
56. Oda SK, Strauch P, Fujiwara Y, Al-Shami A, Oravecz T, et al. (2013) Lysophosphatidic Acid inhibits CD8 T cell activation and control of tumor progression. Cancer Immunol Res 1: 245-255.
57. Knowlden S GS (2012) LPAR2 (lysophosphatidic acid receptor 2). Atlas Genet Cytogenet Oncol Haematol.
58. Stam JC, Michiels F, van der Kammen RA, Moolenaar WH, Collard JG (1998) Invasion of T-lymphoma cells: cooperation between Rho family GTPases and lysophospholipid receptor signaling. EMBO J 17: 4066-4074.
59. Zheng Y, Kong Y, Goetzl EJ (2001) Lysophosphatidic acid receptor-selective effects on Jurkat T cell migration through a Matrigel model basement membrane. J Immunol 166: 2317-2322.
60. Xu J, Lai YJ, Lin WC, Lin FT (2004) TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor. J Biol Chem 279: 10459-10468.
61. Lai YJ, Lin VT, Zheng Y, Benveniste EN, Lin FT (2010) The adaptor protein TRIP6 antagonizes Fas-induced apoptosis but promotes its effect on cell migration. Mol Cell Biol 30: 5582-5596.
62. Cahalan MD, Parker I (2008) Choreography of cell motility and interaction dynamics imaged by two-photon microscopy in lymphoid organs. Annu Rev Immunol 26: 585-626.
63. Lay MD, Zhang L, Ribeiro RM, Mueller SN, Belz GT, et al. (2009) Kinetics of major histocompatibility class I antigen presentation in acute infection. J Immunol 182: 902-911.
64. Roozendaal R, Mempel TR, Pitcher LA, Gonzalez SF, Verschoor A, et al. (2009) Conduits mediate transport of low-molecular-weight antigen to lymph node follicles. Immunity 30: 264-276.
65. Clement CC, Cannizzo ES, Nastke MD, Sahu R, Olszewski W, et al. (2010) An expanded self-antigen peptidome is carried by the human lymph as compared to the plasma. PLoS One 5: e9863.
66. Sixt M, Kanazawa N, Selg M, Samson T, Roos G, et al. (2005) The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity 22: 19-29.
67. Itano AA, McSorley SJ, Reinhardt RL, Ehst BD, Ingulli E, et al. (2003) Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 19: 47-57.
68. Zaslavsky A, Singh LS, Tan H, Ding H, Liang Z, et al. (2006) Homo- and hetero-dimerization of LPA/S1P receptors, OGR1 and GPR4. Biochim Biophys Acta 1761: 1200-1212.